854056-07-8
854056-07-8 结构式
基本信息
罗哌卡因甲磺酸盐
甲磺酸罗哌卡因中间体
甲磺酸罗哌卡因854056-07-8
N-(2,6-二甲基苯基)-1-丙基哌啶-2-甲酰胺甲磺酸盐
N-(2,6-二甲基苯基)-1-正丙基哌啶-2-甲酰胺甲磺酸盐
S-(-)-N-(2,6-二甲基苯基)-1-丙基-2-哌啶甲酰胺甲磺酸盐
Ropivacaine Mesylate API
Ropivacaine mesylate USP/EP/BP
Ropivacaine Mesylate Injection
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monomethanesulfonate
Ropivacaine mesylate (2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide monomethanesulfonate
常见问题列表
图1为甲磺酸罗哌卡因注射液
有关甲磺酸罗哌卡因的概述、药理作用、临床应用是由Chemicalbook的丁红编辑整理。（2015-12-02）
2.硬膜外阻滞。
3.外周神经阻滞。
4.蜘网膜下腔阻滞。
5.局部静脉麻醉。
6.术后镇痛。
7.产科麻醉。
8.分娩镇痛。
IC50: sodium ion influxIC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)
Epidural administration of Ropivacaine mesylate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.
Ropivacaine mesylate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).
Ropivacaine mesylate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.
Ropivacaine mesylate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.
| Animal Model: | Adult Sprague-Dawley rats (300-400g) |
| Dosage: | 1 μM |
| Administration: | Infusion (added to the perfusate reservoir) |
| Result: | Attenuated pressure-dependent increases in filtration coefficient (K f ). |